gsk_boronia_australia

GSK to axe 720 positions at Belgian vaccine facility

pharmafile | February 7, 2020 | News story | Manufacturing and Production, Medical Communications GSK, job cuts, pharma 

GlaxoSmithKline has announced a cull of staff at its vaccine production site in Belgium, with 720 employees facing the axe.

The decision comes as part of a two-year restructuring strategy, and just ahead of the company’s plans to split itself into a consumer products business and a branded drug development business.

In addition to these 720 job cuts, the company has also confirmed It will not seek to renew the contracts of 215 temporary employees. The overall, the wave of cuts will affect operations in manufacturing, R&D and global support, with mostly managers bearing the brunt.

GSK is the largest pharmaceutical employer in the country, employing around 9,000 staff.

“I understand the emotion that this announcement can arouse among our employees who make enormous efforts every day to ensure the availability of our vaccines to those who need them,” commented Patrick Florent, Managing Director of GSK Vaccines in Belgium. “It is important that we start discussions today with our social partners through the Works Council to examine in more detail the potential impact of this transformation project on our employees. GSK takes its responsibilities to its employees very seriously and will ensure that the proposed changes are addressed in a responsible manner, in accordance with company values. Finally, I would like to reconfirm GSK’s strategic commitment in Belgium, which will remain at the heart of vaccine operations.”

Matt Fellows

 

Related Content

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

GSK has announced that the US Food and Drug Administration (FDA) has accepted its supplemental …

GSK shares results from phase 3 trial for gonorrhoea treatment

GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential …

GSK’s meningococcal vaccine candidate accepted for FDA review

GSK has announced that the US Food and Drug Administration (FDA) has accepted for review …

Latest content